Charles River Laboratories Announces Fourth-Quarter and Full-Year 2016 Results from Continuing Operations and Provides 2017 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
Charles River Labs (CRL) PT Raised to $84 at UBS Following Strong 4Q Results
February 15, 2017 9:31 AM ESTUBS analyst Jonathan Groberg maintains Sell rating and raises price target on Charles River Laboratories International (NYSE: CRL) to $84 (from $78), as the company announced revenue and EPS figures above consensus projections.
Groberg comments, "CRL reported 4Q16 results with reported revenue of $467m,... More
Charles River Labs (CRL) PT Raised to $104 at Jefferies Following Strong 4Q Results
February 15, 2017 8:11 AM ESTJefferies analyst David Windley reiterates Buy rating and raises price target on Charles River Laboratories (NYSE: CRL), as the company reported 2016 fourth quarter revenue and EPS above consensus.
Windley comments, "4Q results far outpaced consensus revenue/EPS driven by strength across the 3 segments.... More
Charles River Laboratories (CRL) Tops Q4 EPS by 10c, Guides FY17 EPS In-Line
February 14, 2017 6:33 AM ESTCharles River Laboratories (NYSE: CRL) reported Q4 EPS of $1.21, $0.10 better than the analyst estimate of $1.11. Revenue for the quarter came in at $466.8 million versus the consensus estimate of $441.64 million.
GUIDANCE:
Charles River Laboratories sees FY2017 EPS of $5.00-$5.10, versus the... More
